Data as of Q4 2025 (Dec 31, 2025)

JASPER THERAPEUTICS, INC.

(JSPR)

Financial Statements · SEC EDGAR XBRL

Net Income
-$75.8M
-6.4%
EPS
$-3.95
+19.2%
Op. Income
-$83.9M
-10.0%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Cost of Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$41.6M
$34.3M
-
-
-
$63.1M
$55.8M
$51.8M
$34.6M
$25.4M
$83.9M
$76.2M
$68.9M
$51.2M
$36.8M
-$83.9M
-$76.2M
-$68.9M
-$51.2M
-$36.8M
-$2.2M
-$88K
-$246K
$586K
-$80K
-
$2K
$2K
-
-
-$75.8M
-$71.3M
-$64.5M
-$37.7M
-$30.6M
$-3.95
$-4.89
$-6.18
$-10.33
$-2.69
$-3.95
$-4.89
$-6.18
$-10.33
$-2.69
19.2M
14.6M
10.4M
3.6M
11.4M